– ABL Bio et GSK concluent un accord multi-programmes pour développer de nouveaux médicaments contre les maladies neurodégénératives. – Les programmes exploiteront la technologie de la plateforme Grabody-B d’ABL Bio pour délivrer efficacement des molécules […]
– ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases – Programs will leverage ABL Bio’s Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier – […]
– ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases – Programs will leverage ABL Bio’s Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier – […]
– MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio’s ABL103 in a Phase 1b/2 clinical trial SEONGNAM, South Korea, Oct. 4, 2024 /PRNewswire/ — ABL Bio (CEO Sang Hoon Lee), a company […]
en How can I help you? :)
العربية
简体中文
Dansk
Nederlands
Esperanto
Suomi
Français
Deutsch
עִבְרִית
हिन्दी
Íslenska
Italiano
日本語
한국어
Монгол
नेपाली
Norsk bokmål
Português
Русский
Samoan
Afsoomaali
Español
Svenska
ไทย
Türkçe
Українська
יידיש
Zulu